

Drug Review

Recently Introduced Products

Volume V, Issue 5

Drug Name	Indication	Potential Plan Impact
DuoTrav ophthalmic solution	Treatment of glaucoma or ocular hypertension	\$
Hepsera 10mg tablets	Treatment of lamivudine-resistant chronic hepatitis B patients or chronic hepatitis B patients with HIV who don't require HIV treatment	\$\$

\$ Little increase estimated in drug plan expenditure
\$\$ Drug plan expenditure estimated to be somewhat increased
\$\$\$ Potential for large increase in drug plan expenditure

Enablex and Trosec – New options in bladder control

Overactive bladder (“OAB”) is a problem that more and more Canadians face as we age. It is estimated that over 1.5 Million Canadians are affected by loss of bladder or bowel control; the majority being older adults¹. In Canadian households, 25% of females and 10% of males have urinary incontinence, and as high as 50% for elderly men and women living in institutions.

Nonpharmacologic therapies include modifying lifestyle (e.g. stopping caffeine and alcohol intake) and behaviour (e.g. bladder training and pelvic floor exercises) to prevent urine loss². Improved results may be obtained by combining these strategies with drug treatment or drug treatment alone.

Anticholinergic agents are the drug treatment of choice in OAB. Anticholinergic agents block muscarinic receptor sites, thereby inhibiting bladder contractions (which cause urgency and urine loss) and stabilizing the bladder muscle. Currently available agents include immediate and extended-release formulations of Ditropan® (oxybutynin) and Detrol® (tolterodine).

Enablex and Trosec represent new options in the treatment of OAB. They are both selective muscarinic receptors antagonists i.e. they target the muscarinic receptors in the bladder specifically. As such, there are decreased adverse effects - particularly in the central nervous system. Symptoms can include drowsiness, cognitive impairment or confusion in patients with dementia. The most common side effects of Enablex and Trosec are dry-mouth, constipation and headache. Trosec is taken twice daily before food and Enablex is taken once daily with or without food.

Enablex costs \$1.58 per day and Trosec costs \$1.50 per day. In contrast, immediate-release Detrol® costs \$1.92 per day and the extended-release version costs \$1.93 per day. Ditropan® and Detrol® are fully covered under all ClaimSecure drug programs. Enablex and Trosec not only have a better side-effect profile, but they also cost less. Therefore, both Enablex and Trosec will be fully covered under ALL ClaimSecure drug programs, including ClaimSecure's **Managed Formularies**. *If you require additional information about Enablex or Trosec, please contact Shellina Sevany in ClaimSecure's Clinical Services Department at (905) 949-3025 or 1-888-479-7587 ext.3025.*

Recommendation: Full Coverage

ClaimSecure reserves the right to amend in part or in its entirety stated special authorization clinical guidelines

References:

1. Incontinence. [Ottawa]: Health Canada: Seniors Info Exchange, 1999. Accessed May 10, 2006 at URL: http://www.health.gc.ca/seniors-aines/pubs/info_exchange/pdf/incontinence_e.pdf.
2. Hashim H, Abrams P. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. Drugs. 2004;64(15):1643-56.

